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Reply to “Human genetic studies on osteoarthritis from clinicians’ viewpoints”Dear Sir,
Akune and Kawaguchi1 in an editorial comment to the paper by
Kerkhof et al.2 raise the question whether conventional osteoar-
thritis (OA) genetic studies are worth the investment. The authors
have misunderstood the scope and the conclusions of our paper
by assuming they were limited to genetic OA research only. On
the contrary, problems of disease deﬁnition affect classical observa-
tional epidemiological, biomarker or clinical trial studies and
genetic studies are among the few to deal with the heterogeneity
in the OA deﬁnitions.
Akune and Kawaguchi1 state that “the conventional OA genetic
studies do not seem to have been performed with sufﬁcient scientiﬁc
strictness, even as compared to those on other common diseases”.
We strongly disagree because recent genetic studies have set very
strict rules not only on the selection of cases and controls included
in the studies but also on signiﬁcance threshold which is set at the
level of P< 5108. Furthermore, genetic studies have highlighted
the need for replication of ﬁndings, thus reducing the false-positive
signals and supporting the need for collaborative efforts. Genome-
wide association studies (GWAS) have revealed a considerable
amount of information about the genetic architecture of the
disease3 and we now know that sample sizes in the excess of
7000 cases and 7000 controls are needed to detect common vari-
ants as genome-wide signiﬁcant for this disease. Other complex
common diseases such as hypertension remained refractive to
genetic association studies until several tens of thousands of
samples accrued.
Akune and Kawaguchi1 raised four different issues which we
comment on:
1. Stringency of disease deﬁnition: We agree that novel (sub)
phenotypes are necessary in OA to elucidate disease pathogenesis
and to ﬁnd new genetic variants, biochemical markers and thera-
peutic agents. However, whether the KOACAD system andMagnetic
Resonance Imaging (MRI) will serve as “optimal measures for the
deﬁnition of OA in the near future, just as bone mineral density
does in osteoporosis” is questionable. Although MRI-imaging of
OA has been around for several years already, it has yet to produce
a reliable parameter/marker for OA (for review see: ref. 4).
2. Appropriate case control selections: Akune and Kawagachi
show in their paper in Table II1 that the prevalence of radiographic
knee OA in the elderly is different in all populations compared to
the Asian ROAD population. However, as shown by Kerkhof et al.
2 the ROAD Study used a different deﬁnition of a K/L score of 2DOI of original article: 10.1016/j.joca.2011.12.006.
1063-4584/$ – see front matter  2011 Published by Elsevier Ltd on behalf of Osteoarth
doi:10.1016/j.joca.2011.09.008than the one originally described by Kellgren and Lawrence. After
standardization of this K/L score the prevalence of radiographic
knee OA in the ROAD study was much lower and similar to Cauca-
sian populations. This reﬂects an entirely different case selection,
not taken into account by the authors. We feel, as do Akune and
Kawaguchi, that indeed there is not only a need for standardization
of case selection, but also of controls. Although it is desirable to
have the control selection standardized in the same sort of manner
as the cases, in practice this is often not achievable.
3. Usefulness of genetic studies for prediction/clinical
management: We agree that genetic loci are not really useful in
prediction of OA since they can add only a few percentages extra
predictive power [improvement in area-under the curve (AUC)]
on top of the classical clinical risk factors for OA5,6. However, the
same might be true for biochemical markers like uCTX-II, a prom-
ising disease marker: when the predictive power of Single Nucleo-
tide Polymorphisms (SNPs) for incident OAwas compared to that of
a well-known biochemical marker uCTX-II (a cartilage degradation
marker) within the Rotterdam Study, we observed that they had
very similar and limited additive predictive value (additive AUC
SNPs: 0.01 versus 0.03 for CTX2, results not published).
These results are neither surprisingnordisappointing. In a recent
analysis of OAGWASdata, Panoutsopoulou et al. showed that OAhas
a polygenic component and that multiple common variants of
modest effect size are likely to underpin its genetic etiology. Genetic
studies have, however, been able to indicate skeletal development
as major etiological pathway in the late onset of OA as it occurs in
the general population7,8. Subsequent, functional analyses in man
and mice indicated the relevance of these genes in the onset of
OA9,10. Inparallel, one biochemicalmarker can only grasp one aspect
of the disease process going on, i.e., cartilage degradation for CTX-II,
limited predictive value of such amarker is logical. Only if amajority
of aspects of the disease are captured in one ormoremarkers a high
predictive value of such a marker could be expected.
4. Pooling of subjects resulting in selection bias: Akune and
Kawaguchi argue that subjects are being pooled which leads to
a selection bias and therefore small effect sizes of the risk alleles.
This is incorrect: in the meta-analyses of the Translational Research
in Europe Applied Technologies for OsteoArthritis (TREAT-OA)
consortium, individual subjects are not pooled and selection bias
is not a problem11,12, only effect sizes of individual studies are
pooled. Further, the fact that small effect sizes are detected in
genetic studies of OA is not likely the result of selection bias. Actu-
ally, the median OR observed in the ﬁeld of genetic epidemiology is
1.413 and even smaller effects at the range of 1.10, 1.20 have been
identiﬁed in the GWAs era (see ref. 5). This does notmean that these
genes are not important in OA, but only that this speciﬁc commonritis Research Society International.
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explained. This inﬂuences the power to detect risk factors for
genetic studies, but also for other clinical studies. So the heteroge-
neous nature of OA affects both genetic and non genetic risk
factors14 and might be one of the reasons why despite intense
research no diseasemodifying drugs are yet approved by regulatory
authorities. To only select controls and cases from a single
population-based cohort as suggested by Akune and Kawaguchi
would merely reduce the power to ﬁnd true signals and lead to
an increase in false-positive signals unlikely not to be replicated
in subsequent replication efforts.
The main conclusion from the editorial is that “genetic studies
seem to be unable to reach a genuine therapeutic target or even
a prognostic marker of OA”. Unfortunately this is true for the
complete OA-ﬁeld and not speciﬁc to genetics. On the other hand,
as the number of samples with detailed OA phenotyping and
genome-wide genotyping increases, it is to be expected that by
2012 there will be sufﬁcient data to make a much more positive
assessment of what genetics can deliver for OA15,16.References
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